Apyx Medical (NASDAQ:APYX) Announces Earnings Results, Beats Expectations By $0.05 EPS

Apyx Medical (NASDAQ:APYX) posted its quarterly earnings results on Thursday. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.05, FiscalAI reports. Apyx Medical had a negative net margin of 14.78% and a negative return on equity of 76.60%. The firm had revenue of $14.03 million for the quarter, compared to analyst estimates of $13.29 million.

Here are the key takeaways from Apyx Medical’s conference call:

• Apyx reported third-quarter revenue of $14 million, up 9% year over year, led by 17% growth in Surgical Aesthetics. OEM revenue fell 41.5%, partially offsetting that growth.
• The company said AYON’s power-liposuction rollout is underway and surgeon feedback has been positive; management sees additional growth potential as it pursues regulatory approvals in international markets, though it gave no approval timelines.
• Apyx reported positive EBITDA on a trailing 12-month basis and $0.4 million in adjusted EBITDA for the quarter, versus a loss a year earlier. Operating cash use also declined year over year, and cash stood at $25.8 million at quarter-end.
• Apyx reaffirmed 2026 revenue guidance of $59 million–$60 million and lowered its operating-expense target to $41 million–$42.5 million from less than $45 million. It now expects full-year gross margins of 63%–64%.

Apyx Medical Price Performance

APYX traded down $0.09 during trading on Friday, reaching $2.97. The stock had a trading volume of 104,287 shares, compared to its average volume of 145,814. The company has a quick ratio of 4.53, a current ratio of 5.68 and a debt-to-equity ratio of 3.19. The firm has a market capitalization of $125.07 million, a price-to-earnings ratio of -14.84 and a beta of 1.47. The stock has a 50 day moving average of $2.74 and a two-hundred day moving average of $3.59. Apyx Medical has a 1-year low of $2.25 and a 1-year high of $5.08.

Key Stories Impacting Apyx Medical

Here are the key news stories impacting Apyx Medical this week:

• Positive Sentiment: Q3 revenue was $14.0 million, ahead of the roughly $13.3 million analysts expected. The quarterly loss of $0.04 per share was also narrower than estimates, and Surgical Aesthetics revenue grew 17%. Apyx Medical Q3 2026 financial results
• Positive Sentiment: Management tightened its 2026 operating expense target to $41 million–$42.5 million, a potential sign of improved cost discipline. Apyx reaffirms guidance and tightens expense target
• Neutral Sentiment: Apyx reaffirmed 2026 revenue guidance of $59 million–$60 million, broadly in line with the $59.4 million consensus estimate. The company also reported the successful full commercial launch of the AYON system’s power liposuction handpiece in Q3; its contribution to future results remains to be seen. Apyx Medical Q3 2026 financial results
• Negative Sentiment: Despite beating estimates, Apyx remained unprofitable, reporting a $0.04-per-share loss and a negative net margin. Sustained growth and progress toward profitability remain important risks for investors. Apyx Medical reports Q3 loss, tops revenue estimates

Analyst Upgrades and Downgrades

APYX has been the subject of a number of analyst reports. HC Wainwright assumed coverage on shares of Apyx Medical in a research report on Monday, July 13th. They issued a “buy” rating and a $7.00 price objective for the company. Zacks Research upgraded Apyx Medical to a “hold” rating in a research note on Tuesday, July 14th. Maxim Group assumed coverage on Apyx Medical in a report on Tuesday, September 29th. They set a “buy” rating and a $6.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Apyx Medical in a research report on Monday, September 21st. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $6.50.

About Apyx Medical

Apyx Medical Corporation develops and commercializes energy-based medical technologies for use in surgical and aesthetic procedures. The company’s platform is based on helium plasma technology, which is designed to deliver controlled energy for soft-tissue coagulation, cutting, and contraction.

Apyx Medical’s principal product line is Renuvion, a system that combines helium plasma with radiofrequency energy. Renuvion devices and handpieces are used by physicians in a range of surgical and aesthetic applications, including procedures intended to coagulate tissue and address skin laxity.